Letter

“Polypill” to fight cardiovascular disease: Patients before populations

BMJ 2003; 327 doi: https://doi.org/10.1136/bmj.327.7418.807 (Published 02 October 2003) Cite this as: BMJ 2003;327:807
  1. Peter Trewby (peter.trewby{at}sdhc-tr.northy.nhs.uk), consultant physician,
  2. Catherine Trewby, general practitioner
  1. Darlington Memorial Hospital, Darlington DL3 6HX
  2. Clifton Court Medical Practice, Darlington DL1 5JN

    EDITOR—Wald and Law's provocative paper and the accompanying editorial on the “Polypill” was disappointing in focusing only on the advantage to the population and ignoring the individual's views of the benefit he or she would wish to see from taking preventive drugs.1 2

    The median threshold of absolute risk reduction below which patients would not wish to take a preventive drug may be as high as 30% over five years. This is far higher than the benefit of the Polypill, which offers a meagre 7% reduction over 10 years if started at age 55.3 We and others found this benefit would be acceptable to only one in 10 healthy people.3 If only one in 10 take the Polypill the effect on the population will be negligible.


    Embedded Image

    It all comes down to accurate numerical presentation and framing of the benefits of drugs to patients. As the patient's treatment broker, doctors are duty bound to inform their healthy 55 year old patient that if he or she takes the Polypill for the next 10 years the chance of benefit will be less than 1% per year and that of side effects 6% overall, some of which (such as aspirin related gastro-intestinal haemorrhage) may be life threating1

    Furthermore, if the polypill is successful their patient's chance of dying from cancer, trauma, and degenerative brain disease will increase with the effectiveness of the Polypill, as even with Polypill treatment, mortality will remain stubbornly 100%.

    Some patients will do anything to prevent a heart attack or stroke. Some will take any treatment if their doctor recommends it. In the modern health service, whose focus is increasingly on health promotion rather than treating disease, doctors need to be numerically well informed and to be able to present data on drug effectiveness which are relevant to their patient as a person.

    Journal editors have a tremendous responsibility to support doctors in this task by insisting that authors emphasise figures denoting the reduction in absolute risk. Given these figures for the Polypill, most doctors and patients will be considerably less enthusiastic than the authors of this paper and editorial.

    Footnotes

    • Competing interests None declared.

    References

    1. 1.
    2. 2.
    3. 3.
    View Abstract

    Sign in

    Log in through your institution

    Free trial

    Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
    Sign up for a free trial

    Subscribe